Hepatocellular Carcinoma
If it’s your first time on this website, please read the disclaimer section.
May 11 – May 18, 2026
Overall Survival Among Patients With Hepatocellular Carcinoma Treated With External Beam Radiation Therapy: Individual Patient Data Outcomes From a Multinational Cohort.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This multinational cohort study analyzed individual patient data from 4,913 patients with hepatocellular carcinoma (HCC) treated with external beam radiation therapy (EBRT) to assess overall survival (OS). Median OS was 6.8 years for BCLC-0 and 4.6 years for BCLC-A stage; in treatment-naïve patients, median OS was not reached for BCLC-0 and was 5.4 years for BCLC-A. The study directly addresses your interest in cancer-focused research, providing robust evidence that EBRT yields OS outcomes comparable to resection and thermal ablation for early-stage HCC. Clinically, these data support incorporating EBRT into BCLC decision-making algorithms for very early- and early-stage HCC patients.
10.1200/JCO-25-02399
May 04 – May 11, 2026
Hepatitis B: A Review.
JAMA-J AM MED ASSOC · Q1 JOURNAL - RANK #4/332TOP-TIER
This clinical review examines the epidemiology, diagnosis, and management of Hepatitis B virus (HBV), which affects 254 million people globally. Key findings highlight that chronic HBV carries an 8% to 15% five-year risk of cirrhosis, with cirrhotic patients facing a 3% to 5% annual incidence of hepatocellular carcinoma (HCC). For clinicians focused on oncology, the study demonstrates that antiviral therapies like tenofovir reduce HCC risk by approximately 50% and recommends biannual ultrasound and alpha-fetoprotein surveillance for high-risk individuals. Ultimately, the review underscores that effective HBV management and universal vaccination are primary strategies for preventing liver cancer and reducing virus-related mortality.
10.1001/jama.2026.6070
Apr 27 – May 04, 2026
International multisociety Delphi consensus for liver tumour thermal ablation: margin assessment.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This international multisociety Delphi consensus aimed to standardize ablation margin assessment in liver tumour thermal ablation, utilizing a modified Delphi process with 72 experts. Formal consensus was reached for 150 (75%) of 199 statements, with strong agreement observed (only 6% disagreement). Experts agreed margins should be quantitatively assessed in 3D with CT/MRI, preferably intraprocedurally, and categorized as A0, A1, or A2. This provides best-practice recommendations for liver cancer treatment, standardizing practices to improve uniform outcomes for patients.
10.1016/S1470-2045(26)00143-9
International multisociety Delphi consensus for liver tumour thermal ablation: procedural and practice standards.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This international Delphi consensus aimed to standardize procedural and practice guidelines for thermal ablation of primary and metastatic liver tumours. Seventy-two experts achieved consensus on 94 (70%) of 135 statements across five domains, including credentialing and indications. Key findings emphasize prioritizing the percutaneous approach, ensuring margin adequacy, and recommending experienced operators (>100 cases) for complex ablations. This study directly informs clinicians treating liver cancer, providing crucial guidance to improve consistency, safety, and oncological outcomes in cancer care.
10.1016/S1470-2045(26)00114-2
Apr 20 – Apr 27, 2026
Histotripsy and the IDEAL Framework: A Clarion Call for the Responsible and Evidence-Based Application of New Technology.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This editorial examines the rapid adoption of histotripsy for liver tumor treatment and proposes using the IDEAL framework to ensure evidence-based implementation. The authors highlight that current adoption has outpaced clinical evidence, driven by social media and marketing, potentially compromising safety and efficacy standards. For oncology clinicians, the article provides a structured approach to evaluating this novel non-invasive ablation technology amidst commercial pressures. It advocates for rigorous, phased evaluation to optimize patient selection and clinical outcomes in the management of hepatic malignancies.
10.1200/JCO-26-00174
Apr 13 – Apr 20, 2026
The versatile interplay between steatotic liver disease and liver cancer.
NAT REV CANCER · Q1 JOURNAL - RANK #3/326TOP-TIER
This review article examines the molecular, genetic, and cellular mechanisms by which steatotic liver diseases (MASLD and alcoholic liver disease) progress to liver cancer, highlighting that these diseases are leading causes of liver cancer development. The authors discuss distinct pathophysiological pathways for MASH-associated and ASH-associated liver cancers despite common histopathological features, and cover developments in risk assessment, differential diagnosis, and therapeutic management. The research is directly relevant to a clinician focused on cancer as it provides a mechanistic understanding of hepatocarcinogenesis within the context of prevalent metabolic and alcohol-related liver diseases. The primary implication is the need for tailored risk assessment and therapeutic strategies for liver cancer arising from different etiologies of steatotic liver disease.
10.1038/s41568-026-00918-y